Quality of lifeNo. of participants: 271(2 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Overall survival: WBRT 4000 cGy/20 fractions BID vs control WBRT (2000 cGy/4‐5 daily fractions)No. of participants: 203(2 RCTs) · patients with newly diagnosed multiple brain metastases
Altered WBRT fractionation schedules showed no clear difference in overall survival: WBRT 4000 cGy/20 fractions BID vs control WBRT… compared with WBRT control (moderate certainty).
1 finding from 1 review
HR 1.18 [0.89, 1.56]
Studies not reported
Moderate
Adverse effectsNo. of participants: 1754(9 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
High
Symptom controlNo. of participants: 1814(3 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Overall brain controlNo. of participants: 203(2 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Neurological function improvement: lower‐dose WBRT vs control dose WBRT (3000 cGy/10 fractions)No. of participants: 1612(5 RCTs) · patients with newly diagnosed multiple brain metastases
Altered WBRT fractionation schedules probably leads to higher neurological function improvement: lower‐dose WBRT vs control dose… compared with WBRT control: neurological function improvement (moderate certainty).
1 finding from 1 review
OR 1.74 [1.06, 2.84]
Studies not reported
Moderate
Neurological function improvement: higher‐dose WBRT vs control dose WBRT (3000 cGy/10 fractions)No. of participants: 1480(4 RCTs) · patients with newly diagnosed multiple brain metastases
Altered WBRT fractionation schedules showed no clear difference in neurological function improvement: higher‐dose WBRT vs control dose… compared with WBRT control: neurological function improvement (moderate certainty).
1 finding from 1 review
OR 1.14 [0.92, 1.42]
Studies not reported
Moderate
Overall survivalNo. of participants: 2631(8 RCTs) · patients with newly diagnosed multiple brain metastases
WBRT with radiosensitisers (radiosen) showed no clear difference in overall survivalNo. of participants: 2631(8 RCTs) compared with WBRT alone (moderate certainty).
1 finding from 1 review
HR 1.05 [0.99, 1.12]
Studies not reported
Moderate
Intervention not reported
Annualised relapse rate (ARR) (number of relapses per patient per year) · [People] with [Multiple Sclerosis]
1 finding from 1 review
Intervention not reported
Expanded Disability Status Scale (EDSS) score · [People] with [Multiple Sclerosis]
1 finding from 1 review
Intervention not reported
MRI gadolinium‐enhancing T1 lesions · [People] with [Multiple Sclerosis]
1 finding from 1 review
Intervention not reported
Serious adverse events · [People] with [Multiple Sclerosis]
1 finding from 1 review
Intervention not reported
Minor adverse events · [People] with [Multiple Sclerosis]
1 finding from 1 review
Outcomes (see also Table 3) · people with multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Knowledge · people with multiple sclerosis
1 finding from 1 review
Decision making · people with multiple sclerosis
1 finding from 1 review
Quality of life · people with multiple sclerosis
1 finding from 1 review
Adverse events · people with multiple sclerosis
1 finding from 1 review
Intervention not reported
Overall survival## · patients with multiple myeloma
The intervention showed no clear difference in overall survival## (moderate certainty).
1 finding from 1 review
Intervention not reported
Progression‐free survival### · patients with multiple myeloma
The intervention showed no clear difference in progression‐free survival### (low certainty).
1 finding from 1 review